Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Mgcd516
1. 1123837-84-2
2. Mgcd516
3. Mg-516
4. Mgcd-516
5. Sitravatinib [inn]
6. Cwg62q1vtb
7. Sitravatinib (mgcd516)
8. Mg-91516
9. Mg516
10. 1-n'-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
11. N-(3-fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
12. 1,1-cyclopropanedicarboxamide, N-(3-fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)-2-pyridinyl)thieno(3,2-b)pyridin-7-yl)oxy)phenyl)-n'-(4-fluorophenyl)-
13. 1,1-cyclopropanedicarboxamide, N-[3-fluoro-4-[[2-[5-[[(2-methoxyethyl)amino]methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxy]phenyl]-n'-(4- Fluorophenyl)-
14. N-(3-fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)pyridin-2-yl)thieno(3,2-b)pyridin-7-yl)oxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
15. Unii-cwg62q1vtb
16. Sitravatinib (usan/inn)
17. Sitravatinib [usan:inn]
18. Sitravatinib [usan]
19. Schembl172015
20. Sitravatinib [who-dd]
21. Gcd516
22. Gtpl9920
23. Chembl3989926
24. Mgcd516;mg516
25. Gcd-516
26. Dtxsid801100124
27. Bcp29099
28. Ex-a2588
29. Bdbm50467574
30. Nsc788203
31. S8573
32. Zinc164334830
33. Ccg-270287
34. Cs-5652
35. Db15036
36. Nsc-788203
37. Sb17195
38. Ncgc00483926-01
39. Ac-36164
40. Bs-14332
41. Bs166446
42. Hy-16961
43. D11140
44. D83649
45. A910305
46. Q27275860
47. Mgcd516;mgcd-516;mgcd 516;mg516;mg 516;mg-516
48. 1609655-67-5
| Molecular Weight | 629.7 g/mol |
|---|---|
| Molecular Formula | C33H29F2N5O4S |
| XLogP3 | 5.2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 12 |
| Exact Mass | 629.19083192 g/mol |
| Monoisotopic Mass | 629.19083192 g/mol |
| Topological Polar Surface Area | 143 Ų |
| Heavy Atom Count | 45 |
| Formal Charge | 0 |
| Complexity | 1000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Sitravatinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sitravatinib, including repackagers and relabelers. The FDA regulates Sitravatinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sitravatinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Sitravatinib supplier is an individual or a company that provides Sitravatinib active pharmaceutical ingredient (API) or Sitravatinib finished formulations upon request. The Sitravatinib suppliers may include Sitravatinib API manufacturers, exporters, distributors and traders.
Sitravatinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sitravatinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sitravatinib GMP manufacturer or Sitravatinib GMP API supplier for your needs.
A Sitravatinib CoA (Certificate of Analysis) is a formal document that attests to Sitravatinib's compliance with Sitravatinib specifications and serves as a tool for batch-level quality control.
Sitravatinib CoA mostly includes findings from lab analyses of a specific batch. For each Sitravatinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sitravatinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Sitravatinib EP), Sitravatinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sitravatinib USP).
LOOKING FOR A SUPPLIER?
